COVID-19 associated pulmonary aspergillosis in critically-ill patients: a prospective multicenter study in the era of Delta and Omicron variants - OmegaHealth Accéder directement au contenu
Article Dans Une Revue Annals of Intensive Care Année : 2024

COVID-19 associated pulmonary aspergillosis in critically-ill patients: a prospective multicenter study in the era of Delta and Omicron variants

1 Hôpital Henri Mondor
2 Inserm U955 - Molecular virology and immunology – Physiopathology and therapeutic of chronic viral hepatitis (Team 18)
3 IMRB - Institut Mondor de Recherche Biomédicale
4 Epidémiologie des maladies chroniques : impact des interactions gène environnement sur la santé des populations
5 CHRU Lille - Centre Hospitalier Régional Universitaire [CHU Lille]
6 Hôpital Raymond Poincaré (Garches) [GHU AP-HP Université Paris-Saclay]
7 Hôpital Ambroise Paré [AP-HP]
8 CARMAS - Groupe de recherche clinique CARMAS (Cardiovascular and Respiratory Manifestations of Acute lung injury and Sepsis)
9 Hôpital Paul Brousse
10 iPLESP - Institut Pierre Louis d'Epidémiologie et de Santé Publique
11 AP-HP - Hopital Saint-Louis [AP-HP]
12 HIPI (UMR_S_976 / U976) - Immunologie humaine, physiopathologie & immunothérapie
13 INEM - UM 111 (UMR 8253 / U1151) - Institut Necker Enfants-Malades
14 IAME (UMR_S_1137 / U1137) - Infection, Anti-microbiens, Modélisation, Evolution
15 Hôpital Saint-Camille [Bry-sur-Marne]
16 MFP - Microbiologie Fondamentale et Pathogénicité
17 UL - Université de Lorraine
18 DCAC - Défaillance Cardiovasculaire Aiguë et Chronique
19 Hôpital Cochin [AP-HP]
20 Hôpital Avicenne [AP-HP]
21 CEPR - Centre d’Etude des Pathologies Respiratoires (CEPR), UMR 1100
22 MAVIVHe - Morphogénèse et antigénicité du VIH, des Virus des Hépatites et Emergents
23 CHU Rouen
24 RESINFIT - Anti-infectieux : supports moléculaires des résistances et innovations thérapeutiques
25 CIC1435 - Centre d'Investigation Clinique de Limoges
26 CHU Limoges
27 Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Ponchaillou]
28 EHESP - École des Hautes Études en Santé Publique [EHESP]
29 Irset - Institut de recherche en santé, environnement et travail
30 CHU Louise Michel [Clermont-Ferrand]
31 Service d'immunologie clinique et maladies infectieuses [Hôpitaux universitaires CHU Henri Mondor]
32 CHU Henri Mondor [Créteil]
Pierre Bay
Elyanne Gault
  • Fonction : Auteur
  • PersonId : 900497
Matthieu Turpin
  • Fonction : Auteur
Sébastien Jochmans
Aurelia Pitsch
  • Fonction : Auteur
Damien Contou
  • Fonction : Auteur
  • PersonId : 1042428
Amandine Henry
Adrien Joseph
  • Fonction : Auteur
  • PersonId : 1090136
Fabrice Uhel
Damien Roux
  • Fonction : Auteur
  • PersonId : 1053316
Claudio Garcia-Sanchez
  • Fonction : Auteur
David Levy
  • Fonction : Auteur
Sonia Burrel
Julien Mayaux
  • Fonction : Auteur
Cédric Hartard
Frédéric Pene
Flore Rozenberg
  • Fonction : Auteur
  • PersonId : 1121945
Stephane Gaudry
Segolene Brichler
Fabienne Tamion
Alice Moisan
Sébastien Hantz
Bertrand Souweine
  • Fonction : Auteur
  • PersonId : 942585
Cécile Henquell
Françoise Botterel
Christophe Rodriguez
  • Fonction : Auteur
  • PersonId : 1118380
Armand Mekontso-Dessap
Slim Fourati
Nicolas de Prost

Résumé

BACKGROUND: During the first COVID-19 pandemic wave, COVID-19-associated pulmonary aspergillosis (CAPA) has been reported in up to 11-28% of critically ill COVID-19 patients and associated with increased mortality. As new SARS-CoV-2 variants emerged, the characteristics of critically ill COVID-19 patients have evolved, particularly in the era of Omicron. The purpose of this study is to investigate the characteristics of CAPA in the era of new variants. METHODS: This is a prospective multicenter observational cohort study conducted in France in 36 participating intensive care units (ICU), between December 7th, 2021 and April 26th 2023. Diagnosis criteria of CAPA relied on European Confederation of Medical Mycology (ECMM)/International Society for Human and Animal Mycology (ISHAM) consensus criteria. RESULTS: 566 patients were included over the study period. The prevalence of CAPA was 5.1% [95% CI 3.4-7.3], and rose to 9.1% among patients who required invasive mechanical ventilation (IMV). Univariable analysis showed that CAPA patients were more frequently immunosuppressed and required more frequently IMV support, vasopressors and renal replacement therapy during ICU stay than non-CAPA patients. SAPS II score at ICU admission, immunosuppression, and a SARS-CoV-2 Delta variant were independently associated with CAPA in multivariable logistic regression analysis. Although CAPA was not significantly associated with day-28 mortality, patients with CAPA experienced a longer duration of mechanical ventilation and ICU stay. CONCLUSION: This study contributes valuable insights into the prevalence, characteristics, and outcomes of CAPA in the era of Delta and Omicron variants. We report a lower prevalence of CAPA (5.1%) among critically-ill COVID-19 patients than previously reported, mainly affecting intubated-patients. Duration of mechanical ventilation and ICU stay were significantly longer in CAPA patients.
Fichier principal
Vignette du fichier
s13613-024-01296-0.pdf (1.02 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-04577615 , version 1 (16-05-2024)

Licence

Paternité

Identifiants

Citer

Pierre Bay, Étienne Audureau, Sébastien Préau, Raphael Favory, Aurélie Guigon, et al.. COVID-19 associated pulmonary aspergillosis in critically-ill patients: a prospective multicenter study in the era of Delta and Omicron variants. Annals of Intensive Care, 2024, 14 (1), pp.65. ⟨10.1186/s13613-024-01296-0⟩. ⟨hal-04577615⟩
0 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More